Yi He Ling

1.0k total citations
15 papers, 855 citations indexed

About

Yi He Ling is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Yi He Ling has authored 15 papers receiving a total of 855 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Molecular Biology and 2 papers in Genetics. Recurrent topics in Yi He Ling's work include Cancer-related Molecular Pathways (5 papers), Cancer therapeutics and mechanisms (3 papers) and Peptidase Inhibition and Analysis (3 papers). Yi He Ling is often cited by papers focused on Cancer-related Molecular Pathways (5 papers), Cancer therapeutics and mechanisms (3 papers) and Peptidase Inhibition and Analysis (3 papers). Yi He Ling collaborates with scholars based in United States, China and Switzerland. Yi He Ling's co-authors include Román Pérez-Soler, Waldemar Priebe, Adel K. El‐Naggar, Jian Jiang, Peter J. Elliott, Julian Adams, Franco M. Muggia, Leonard Liebes, James F. Holland and Yiyu Zou and has published in prestigious journals such as Molecular Pharmacology, European Journal of Cancer and Cell Research.

In The Last Decade

Yi He Ling

15 papers receiving 833 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yi He Ling United States 12 580 381 113 111 92 15 855
Gennaro Colella Italy 16 800 1.4× 439 1.2× 154 1.4× 106 1.0× 70 0.8× 29 1.1k
Julia Kirshner United States 15 368 0.6× 379 1.0× 97 0.9× 175 1.6× 58 0.6× 30 848
Xianping Shi China 20 683 1.2× 261 0.7× 148 1.3× 154 1.4× 72 0.8× 35 1.0k
Gretchen M. Unger United States 17 1.2k 2.1× 438 1.1× 181 1.6× 85 0.8× 154 1.7× 29 1.6k
Randall Evans United States 13 609 1.1× 220 0.6× 132 1.2× 91 0.8× 124 1.3× 24 991
M V Blagosklonny United States 9 574 1.0× 426 1.1× 130 1.2× 38 0.3× 190 2.1× 11 989
Katja Wosikowski United States 17 459 0.8× 415 1.1× 142 1.3× 29 0.3× 37 0.4× 30 954
A. M. Burger United States 15 799 1.4× 368 1.0× 158 1.4× 45 0.4× 41 0.4× 30 1.2k
Shilpak Chatterjee United States 18 254 0.4× 307 0.8× 76 0.7× 77 0.7× 148 1.6× 40 947

Countries citing papers authored by Yi He Ling

Since Specialization
Citations

This map shows the geographic impact of Yi He Ling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yi He Ling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yi He Ling more than expected).

Fields of papers citing papers by Yi He Ling

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yi He Ling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yi He Ling. The network helps show where Yi He Ling may publish in the future.

Co-authorship network of co-authors of Yi He Ling

This figure shows the co-authorship network connecting the top 25 collaborators of Yi He Ling. A scholar is included among the top collaborators of Yi He Ling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yi He Ling. Yi He Ling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Wang, Qi, Lin Xu, Wenbin Wang, et al.. (2016). [Wound healing following laser cordectomy for early glottic carcinoma].. PubMed. 51(4). 289–93. 1 indexed citations
3.
Ling, Yi He, Miguel Aracil, José Jimeno, Román Pérez-Soler, & Yiyu Zou. (2009). Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models. European Journal of Cancer. 45(10). 1855–1864. 33 indexed citations
4.
Han, Wei, et al.. (2008). GC-rich promoter elements maximally confers estrogen-induced transactivation of LRP16 gene through ERα/Sp1 interaction in MCF-7 cells. The Journal of Steroid Biochemistry and Molecular Biology. 109(1-2). 47–56. 12 indexed citations
5.
Meng, Yuan, Weidong Han, Ke Huang, et al.. (2007). Induction of the LRP16 gene by estrogen promotes the invasive growth of Ishikawa human endometrial cancer cells through the downregulation of E-cadherin. Cell Research. 17(10). 869–880. 27 indexed citations
6.
Yun, Zhong, Lluís López-Barcons, Missak Haigentz, Yi He Ling, & Román Pérez-Soler. (2004). Exogenous expression of H-cadherin in CHO cells regulates contact inhibition of cell growth by inducing p21 expression.. PubMed. 24(6). 1573–9. 11 indexed citations
7.
Ling, Yi He, Leonard Liebes, Jian Jiang, et al.. (2003). Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.. PubMed. 9(3). 1145–54. 225 indexed citations
8.
Ling, Yi He, Leonard Liebes, Bruce Ng, et al.. (2002). PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis.. PubMed. 1(10). 841–9. 161 indexed citations
9.
Pérez-Soler, Román, Bonnie L. Kemp, Qing Wu, et al.. (2000). Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice.. PubMed. 6(12). 4932–8. 63 indexed citations
10.
Ling, Yi He, Yiyu Zou, & Román Pérez-Soler. (2000). Induction of senescence-like phenotype and loss of paclitaxel sensitivity after wild-type p53 gene transfection of p53-null human non-small cell lung cancer H358 cells.. PubMed. 20(2A). 693–702. 18 indexed citations
11.
Ling, Yi He, et al.. (1998). Paclitaxel-induced apoptosis is associated with expression and activation of c-Mos gene product in human ovarian carcinoma SKOV3 cells.. PubMed. 58(16). 3633–40. 39 indexed citations
12.
Ling, Yi He, Adel K. El‐Naggar, Waldemar Priebe, & Román Pérez-Soler. (1996). Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells.. Molecular Pharmacology. 49(5). 832–841. 190 indexed citations
13.
Pérez-Soler, Román, Yi He Ling, Yiyu Zou, & Waldemar Priebe. (1994). Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells. Cancer Chemotherapy and Pharmacology. 34(2). 109–118. 12 indexed citations
14.
Zou, Yiyu, Yi He Ling, Nguyen T. Van, Waldemar Priebe, & Román Pérez-Soler. (1994). Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties.. PubMed. 54(6). 1479–84. 45 indexed citations
15.
Han, Insook, Yi He Ling, Salaam Al-Baker, Abdul R. Khokhar, & Román Pérez-Soler. (1993). Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.. PubMed. 53(20). 4913–9. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026